TY - JOUR
T1 - SEA-scFv as a bifunctional antibody
T2 - Construction of a bacterial expression system and its functional analysis
AU - Sakurai, Naoki
AU - Kudo, Toshio
AU - Suzuki, Masanori
AU - Tsumoto, Kouhei
AU - Takemura, Shin Ichi
AU - Kodama, Hideaki
AU - Ebara, Shinji
AU - Teramae, Atsushi
AU - Katayose, Yu
AU - Shinoda, Masao
AU - Kurokawa, Tadashi
AU - Hinoda, Yuji
AU - Imai, Kohzoh
AU - Matsuno, Seiki
AU - Kumagai, Izumi
PY - 1999/3/5
Y1 - 1999/3/5
N2 - A SEA-antibody single chain Fv (SEA-scFv) fusion protein was produced by bacterial expression system in this study. SEA-scFv has both staphylococcal enterotoxin A (SEA) effects and antibody activity directed at the epithelial mucin core protein MUC1, a cancer associated antigen. It was expressed mostly in the cytoplasm as an insoluble form. The gene product was solubilized by guanidine hydrochloride, refolded by conventional dilution method, and purified using metal-chelating chromatography. The resulting SEA-scFv fusion protein preparation was found to react with MUC1 and MHC class II antigens and had the ability to enhance cytotoxicity of lymphokine activated killer cells with a T cell phenotype against a human bile duct carcinoma cell line, TFK-1, expressing MUC1. This genetically engineered SEA-scFv fusion protein promises to be an important reagent for cancer immunotherapy.
AB - A SEA-antibody single chain Fv (SEA-scFv) fusion protein was produced by bacterial expression system in this study. SEA-scFv has both staphylococcal enterotoxin A (SEA) effects and antibody activity directed at the epithelial mucin core protein MUC1, a cancer associated antigen. It was expressed mostly in the cytoplasm as an insoluble form. The gene product was solubilized by guanidine hydrochloride, refolded by conventional dilution method, and purified using metal-chelating chromatography. The resulting SEA-scFv fusion protein preparation was found to react with MUC1 and MHC class II antigens and had the ability to enhance cytotoxicity of lymphokine activated killer cells with a T cell phenotype against a human bile duct carcinoma cell line, TFK-1, expressing MUC1. This genetically engineered SEA-scFv fusion protein promises to be an important reagent for cancer immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=0033525902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033525902&partnerID=8YFLogxK
U2 - 10.1006/bbrc.1999.0263
DO - 10.1006/bbrc.1999.0263
M3 - Article
C2 - 10066451
AN - SCOPUS:0033525902
SN - 0006-291X
VL - 256
SP - 223
EP - 230
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 1
ER -
